Eli Lilly and Company Company Profile (NYSE:LLY)

About Eli Lilly and Company

Eli Lilly and Company logoEli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company's animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: LLY
  • CUSIP: 53245710
Key Metrics:
  • Previous Close: $82.87
  • 50 Day Moving Average: $77.62
  • 200 Day Moving Average: $76.61
  • 52-Week Range: $1,072,099,000.00 - $64.18
  • Trailing P/E Ratio: 32.12
  • Foreward P/E Ratio: 18.88
  • P/E Growth: 1.64
  • Market Cap: $87.09B
  • Outstanding Shares: 1,072,099,000
  • Beta: 0.3
Profitability:
  • Net Margins: 12.90%
  • Return on Equity: 24.74%
  • Return on Assets: 10.30%
Debt:
  • Debt-to-Equity Ratio: 0.56%
  • Current Ratio: 1.62%
  • Quick Ratio: 1.15%
Additional Links:
Companies Related to Eli Lilly and Company:

Analyst Ratings

Consensus Ratings for Eli Lilly and Company (NYSE:LLY) (?)
Ratings Breakdown: 3 Hold Ratings, 11 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.87)
Consensus Price Target: $87.45 (5.53% upside)

Analysts' Ratings History for Eli Lilly and Company (NYSE:LLY)
Show:
DateFirmActionRatingPrice TargetDetails
2/17/2017Jefferies Group LLCReiterated RatingBuyView Rating Details
2/1/2017Barclays PLCBoost Price TargetBuy$80.00 -> $85.00View Rating Details
2/1/2017BMO Capital MarketsReiterated RatingMarket Perform$70.00 -> $73.00View Rating Details
1/19/2017Citigroup Inc.Set Price TargetBuy$100.00View Rating Details
1/18/2017Goldman Sachs Group, Inc. (The)Reiterated RatingConviction-Buy$92.00View Rating Details
1/18/2017Credit Suisse GroupReiterated RatingOutperform$87.00View Rating Details
12/16/2016Morgan StanleyUpgradeEqual Weight -> Overweight$73.00 -> $82.00View Rating Details
12/7/2016Sanford C. BernsteinReiterated RatingOverweightView Rating Details
11/26/2016Leerink SwannReiterated RatingOutperform$102.00 -> $92.00View Rating Details
11/26/2016J P Morgan Chase & CoReiterated RatingOverweightView Rating Details
11/25/2016Atlantic SecuritiesDowngradeOverweight -> NeutralView Rating Details
10/27/2016Societe GeneraleReiterated RatingHold$78.00View Rating Details
9/20/2016Deutsche Bank AGReiterated RatingBuyView Rating Details
8/2/2016ArgusBoost Price TargetBuy$90.00 -> $95.00View Rating Details
6/15/2016SunTrust Banks, Inc.Reiterated RatingBuyView Rating Details
2/4/2016Berenberg BankBoost Price TargetBuy$105.00 -> $106.00View Rating Details
12/22/2015Bank of America CorpReiterated RatingBuy$104.00 -> $108.00View Rating Details
12/9/2015Piper Jaffray CompaniesReiterated RatingBuyView Rating Details
8/21/2015Cowen and CompanyReiterated RatingOutperform$92.00View Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Eli Lilly and Company (NYSE:LLY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2017        
1/31/2017Q416$0.98$0.95$5.54 billion$5.76 billionViewN/AView Earnings Details
10/25/2016Q316$0.96$0.88$4.23 billion$5.19 billionViewListenView Earnings Details
7/26/2016Q216$0.86$0.86$5.14 billion$5.40 billionViewListenView Earnings Details
4/26/2016Q116$0.85$0.83$4.82 billion$4.87 billionViewListenView Earnings Details
1/28/2016Q415$0.78$0.78$5.33 billion$5.38 billionViewListenView Earnings Details
10/22/2015Q315$0.76$0.89$4.99 billion$4.96 billionViewListenView Earnings Details
7/23/2015Q215$0.74$0.90$4.89 billion$4.98 billionViewListenView Earnings Details
4/23/2015Q115$0.76$0.87$4.62 billion$4.64 billionViewN/AView Earnings Details
1/30/2015Q414$0.74$0.75$5.21 billion$5.12 billionViewN/AView Earnings Details
10/23/2014Q314$0.67$0.66$4.83 billion$4.88 billionViewListenView Earnings Details
7/24/2014Q214$0.65$0.68$4.88 billion$4.94 billionViewN/AView Earnings Details
4/24/2014Q114$0.70$0.70$4.78 billion$4.68 billionViewN/AView Earnings Details
1/30/2014Q413$0.72$0.74$5.46 billion$5.81 billionViewListenView Earnings Details
10/23/2013Q313$1.04$1.11$5.76 billion$5.77 billionViewN/AView Earnings Details
7/24/2013Q2 2013$1.01$1.16$5.82 billion$5.93 billionViewN/AView Earnings Details
4/24/2013Q1 2013$1.05$1.14$5.66 billion$5.60 billionViewN/AView Earnings Details
1/29/2013Q4 2012$0.82$0.85$5.78 billion$5.96 billionViewN/AView Earnings Details
10/24/2012$0.82$0.79ViewN/AView Earnings Details
7/25/2012$0.76$0.83ViewN/AView Earnings Details
4/25/2012$0.80$0.92ViewN/AView Earnings Details
1/31/2012$0.80$0.87ViewN/AView Earnings Details
10/20/2011$1.12$1.13ViewN/AView Earnings Details
7/21/2011$1.18$1.18ViewN/AView Earnings Details
4/18/2011$1.16$1.24ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eli Lilly and Company (NYSE:LLY)
Current Year EPS Consensus Estimate: $4.10 EPS
Next Year EPS Consensus Estimate: $4.39 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.80$0.86$0.83
Q2 20163$0.85$0.88$0.86
Q3 20163$0.90$0.98$0.93
Q4 20162$0.92$0.99$0.96
Q1 20171$0.98$0.98$0.98
Q2 20171$1.05$1.05$1.05
Q3 20171$1.04$1.04$1.04
Q4 20171$1.02$1.02$1.02
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Eli Lilly and Company (NYSE:LLY)
Annual Dividend:$2.08
Dividend Yield:2.51%
Dividend Growth:1.30% (3 Year Average)
Payout Ratio:80.62% (Based on Trailing 12 Months of Earnings)
50.73% (Based on Current Year Consensus EPS Estimate)
47.38% (Based on Next Year Consensus EPS Estimate)
Track Record:2 Years of Consecutive Dividend Growth

Dividend History for Eli Lilly and Company (NYSE:LLY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/13/2016quarterly$0.523.03%2/13/20172/15/20173/10/2017
10/17/2016quarterly$0.512.59%11/10/201611/15/201612/9/2016
6/20/2016quarterly$0.512.81%8/11/20168/15/20169/9/2016
5/2/2016quarterly$0.512.68%5/11/20165/13/20166/10/2016
12/8/2015quarterly$0.512.43%2/10/20162/12/20163/10/2016
10/19/2015quarterly$0.502.57%11/10/201511/13/201512/10/2015
6/15/2015quarterly$0.502.42%8/12/20158/14/20159/10/2015
5/4/2015quarterly$0.502.78%5/14/20155/18/20156/10/2015
12/15/2014quarterly$0.502.89%2/11/20152/13/20153/10/2015
10/20/2014quarterly$0.493.03%11/12/201411/14/201412/10/2014
6/16/2014quarterly$0.493.31%8/13/20148/15/20149/10/2014
5/5/2014quarterly$0.493.35%5/13/20145/15/20146/10/2014
12/16/2013quarterly$0.493.98%2/12/20142/14/20143/10/2014
10/21/2013quarterly$0.493.91%11/13/201311/15/201312/10/2013
6/18/2013quarterly$0.493.82%8/13/20138/15/20139/10/2013
5/6/2013quarterly$0.493.62%5/14/20135/16/20136/10/2013
12/17/2012quarterly$0.493.96%2/13/20132/15/20133/8/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Eli Lilly and Company (NYSE:LLY)
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 75.15%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/17/2017Lilly Endowment IncMajor ShareholderSell230,000$80.27$18,462,100.00View SEC Filing  
2/6/2017Alfonso G ZuluetaSVPSell15,000$77.66$1,164,900.00View SEC Filing  
2/3/2017Derica W RiceEVPSell11,162$77.14$861,036.68View SEC Filing  
2/2/2017Donald A ZakrowskiInsiderSell2,000$77.52$155,040.00View SEC Filing  
2/1/2017Lilly Endowment IncMajor ShareholderSell220,000$77.35$17,017,000.00View SEC Filing  
12/16/2016Lilly Endowment IncMajor ShareholderSell200,000$72.59$14,518,000.00View SEC Filing  
12/16/2016Melissa S BarnesInsiderSell2,093$82.23$172,107.39View SEC Filing  
12/16/2016R David HooverDirectorBuy500$71.85$35,925.00View SEC Filing  
12/16/2016Susan MahonySVPSell20,242$72.65$1,470,581.30View SEC Filing  
10/5/2016Maria A CroweInsiderSell2,248$81.37$182,919.76View SEC Filing  
8/15/2016Jackson P TaiDirectorBuy5,773$80.43$464,322.39View SEC Filing  
8/12/2016Jackson P TaiDirectorBuy2,560$80.42$205,875.20View SEC Filing  
7/29/2016Lilly Endowment IncMajor ShareholderSell205,000$82.94$17,002,700.00View SEC Filing  
7/28/2016Donald A ZakrowskiInsiderSell1,213$83.16$100,873.08View SEC Filing  
7/28/2016Lilly Endowment IncMajor ShareholderSell240,000$82.87$19,888,800.00View SEC Filing  
7/12/2016Lilly Endowment IncMajor ShareholderSell210,000$79.54$16,703,400.00View SEC Filing  
7/7/2016Lilly Endowment IncMajor ShareholderSell225,000$79.14$17,806,500.00View SEC Filing  
6/30/2016Lilly Endowment IncMajor ShareholderSell215,000$78.46$16,868,900.00View SEC Filing  
6/29/2016Lilly Endowment IncMajor ShareholderSell220,000$77.86$17,129,200.00View SEC Filing  
6/10/2016Melissa S BarnesSVPSell992$73.77$73,179.84View SEC Filing  
5/31/2016Lilly Endowment IncMajor ShareholderSell200,000$75.12$15,024,000.00View SEC Filing  
5/12/2016Jackson P TaiDirectorBuy1,080$75.75$81,810.00View SEC Filing  
5/12/2016Lilly Endowment IncMajor ShareholderSell190,000$75.86$14,413,400.00View SEC Filing  
5/2/2016Donald A ZakrowskiCAOSell1,600$75.86$121,376.00View SEC Filing  
4/29/2016Lilly Endowment IncMajor ShareholderSell180,000$75.44$13,579,200.00View SEC Filing  
4/27/2016Alfonso G ZuluetaSVPSell12,000$76.27$915,240.00View SEC Filing  
4/8/2016Lilly Endowment IncMajor ShareholderSell200,000$74.29$14,858,000.00View SEC Filing  
2/5/2016Stephen F FrySVPSell15,230$78.87$1,201,190.10View SEC Filing  
2/3/2016David A. RicksSVPSell5,733$77.66$445,224.78View SEC Filing  
2/3/2016Derica W. RiceCFOSell10,483$77.78$815,367.74View SEC Filing  
2/1/2016Jackson P TaiDirectorBuy3,170$78.62$249,225.40View SEC Filing  
1/29/2016Alfonso G ZuluetaSVPSell5,000$78.75$393,750.00View SEC Filing  
12/21/2015Lilly Endowment IncMajor ShareholderSell205,000$86.00$17,630,000.00View SEC Filing  
12/15/2015Lilly Endowment IncMajor ShareholderSell215,000$85.60$18,404,000.00View SEC Filing  
12/9/2015Enrique A ConternoVPSell25,000$83.88$2,097,000.00View SEC Filing  
12/2/2015Lilly Endowment Incmajor shareholderSell210,000$85.09$17,868,900.00View SEC Filing  
11/20/2015Lilly Endowment Incmajor shareholderSell205,000$84.54$17,330,700.00View SEC Filing  
10/29/2015Lilly Endowment Incmajor shareholderSell200,000$82.28$16,456,000.00View SEC Filing  
10/9/2015Lilly Endowment Incmajor shareholderSell215,000$85.86$18,459,900.00View SEC Filing  
10/5/2015Lilly Endowment Incmajor shareholderSell260,000$86.46$22,479,600.00View SEC Filing  
9/18/2015Lilly Endowment Incmajor shareholderSell250,000$89.04$22,260,000.00View SEC Filing  
6/10/2015Lilly Endowment IncMajor ShareholderSell210,000$82.39$17,301,900.00View SEC Filing  
6/4/2015Lilly Endowment IncMajor ShareholderSell200,000$77.90$15,580,000.00View SEC Filing  
5/29/2015Jeffrey N SimmonsSVPSell20,000$78.08$1,561,600.00View SEC Filing  
5/20/2015Lilly Endowment IncMajor ShareholderSell190,000$73.43$13,951,700.00View SEC Filing  
5/15/2015Lilly Endowment IncMajor ShareholderSell200,000$72.83$14,566,000.00View SEC Filing  
5/8/2015Lilly Endowment IncMajor ShareholderSell195,000$73.28$14,289,600.00View SEC Filing  
5/1/2015Lilly Endowment IncMajor ShareholderSell200,000$73.09$14,618,000.00View SEC Filing  
3/30/2015Lilly Endowment IncMajor ShareholderSell180,000$73.94$13,309,200.00View SEC Filing  
3/23/2015Lilly Endowment IncMajor ShareholderSell190,000$76.97$14,624,300.00View SEC Filing  
3/9/2015Stephen F FrySVPSell4,000$69.27$277,080.00View SEC Filing  
2/4/2015David A RicksSVPSell3,147$69.99$220,258.53View SEC Filing  
2/4/2015Derica W RiceCFOSell5,316$70.00$372,120.00View SEC Filing  
2/4/2015Jan M LundbergEVPSell11,085$70.08$776,836.80View SEC Filing  
2/3/2015Jan M LundbergEVPSell121,711$70.78$8,614,704.58View SEC Filing  
2/2/2015David A RicksSVPSell4,769$71.51$341,031.19View SEC Filing  
2/2/2015Derica W RiceCFOSell10,068$71.84$723,285.12View SEC Filing  
12/4/2014Lilly Endowment IncMajor ShareholderSell190,000$71.92$13,664,800.00View SEC Filing  
12/2/2014Lilly Endowment IncMajor ShareholderSell180,000$70.14$12,625,200.00View SEC Filing  
11/13/2014Lilly Endowment IncMajor ShareholderSell200,000$67.73$13,546,000.00View SEC Filing  
11/5/2014Lilly Endowment IncMajor ShareholderSell180,000$67.00$12,060,000.00View SEC Filing  
11/4/2014Fionnuala M WalshSVPSell15,000$67.00$1,005,000.00View SEC Filing  
11/3/2014Enrique A ConternoVPSell5,000$66.03$330,150.00View SEC Filing  
10/31/2014Fionnuala M WalshSVPSell7,376$66.58$491,094.08View SEC Filing  
10/31/2014Lilly Endowment IncMajor ShareholderSell190,000$66.40$12,616,000.00View SEC Filing  
10/30/2014Lilly Endowment IncMajor ShareholderSell175,000$66.58$11,651,500.00View SEC Filing  
10/24/2014Maria A CroweInsiderSell2,750$65.77$180,867.50View SEC Filing  
10/6/2014Lilly Endowment IncMajor ShareholderSell210,000$65.63$13,782,300.00View SEC Filing  
10/1/2014Enrique A ConternoVPSell5,000$64.86$324,300.00View SEC Filing  
9/30/2014Lilly Endowment IncMajor ShareholderSell200,000$65.07$13,014,000.00View SEC Filing  
9/10/2014Lilly Endowment IncMajor ShareholderSell210,000$64.77$13,601,700.00View SEC Filing  
9/3/2014Lilly Endowment IncMajor ShareholderSell200,000$63.99$12,798,000.00View SEC Filing  
9/2/2014Enrique A ConternoVPSell5,000$63.60$318,000.00View SEC Filing  
7/29/2014Lilly Endowment IncMajor ShareholderSell250,000$63.03$15,757,500.00View SEC Filing  
7/28/2014Susan MahonySVPSell2,065$63.30$130,714.50View SEC Filing  
7/25/2014Enrique A ConternoVPSell10,000$63.79$637,900.00View SEC Filing  
7/25/2014Susan MahonySVPSell30,000$63.90$1,917,000.00View SEC Filing  
7/1/2014Lilly Endowment IncMajor ShareholderSell235,000$62.30$14,640,500.00View SEC Filing  
6/25/2014Lilly Endowment IncMajor ShareholderSell245,000$62.68$15,356,600.00View SEC Filing  
6/20/2014Lilly Endowment IncMajor ShareholderSell230,000$61.55$14,156,500.00View SEC Filing  
6/16/2014Lilly Endowment IncMajor ShareholderSell200,000$58.73$11,746,000.00View SEC Filing  
6/5/2014Lilly Endowment IncMajor ShareholderSell190,000$59.53$11,310,700.00View SEC Filing  
5/21/2014Lilly Endowment Incmajor shareholderSell230,000$58.90$13,547,000.00View SEC Filing  
5/12/2014Jackson TaiDirectorBuy17,157$59.19$1,015,522.83View SEC Filing  
5/12/2014Lilly Endowment Incmajor shareholderSell210,000$59.33$12,459,300.00View SEC Filing  
5/6/2014Lilly Endowment Incmajor shareholderSell190,000$58.79$11,170,100.00View SEC Filing  
4/29/2014Lilly Endowment Incmajor shareholderSell200,000$59.43$11,886,000.00View SEC Filing  
4/28/2014Lilly Endowment Incmajor shareholderSell150,000$58.64$8,796,000.00View SEC Filing  
8/15/2013Enrique ConternoVPSell5,000$53.79$268,950.00View SEC Filing  
7/29/2013Jacques TapieroSVPSell7,500$53.74$403,050.00View SEC Filing  
7/15/2013Enrique A ConternoVPSell5,000$51.43$257,150.00View SEC Filing  
6/17/2013Enrique A ConternoVPSell5,000$52.45$262,250.00View SEC Filing  
5/15/2013Enrique A ConternoVPSell5,000$56.15$280,750.00View SEC Filing  
5/10/2013Jeffrey N SimmonsSVPSell10,000$54.49$544,900.00View SEC Filing  
3/26/2013Susan MahonySVPSell5,000$56.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Eli Lilly and Company (NYSE:LLY)
DateHeadline
News IconBuy generic Viagra onlie price - buy viagra online usa - buy viagra now - 9,758 Completed ORDERS Today! (NYSE:LLY)
gamingillustrated.com - February 25 at 5:58 PM
News IconNatural Viagra - Canadian Pharmacy online - Levitra Cost - 5,177 Completed ORDERS Today! (NYSE:LLY)
haitiantimes.com - February 25 at 5:58 PM
News IconEli Lilly and Company (NYSE:LLY) Surged 1.83% (NYSE:LLY)
latribunadecanarias.com - February 25 at 5:58 PM
News IconForward Earnings Estimate of Eli Lilly and Company(LLY) (NYSE:LLY)
www.graffiotech.com - February 25 at 5:58 PM
News IconCleararc Capital Inc. Has $1606000 Position in Eli Lilly and Company (LLY) (NYSE:LLY)
prensariotiretail.com - February 25 at 5:58 PM
News IconShares of Eli Lilly and Company (LLY) Sees Large Outflow of Money (NYSE:LLY)
hoyentv.com - February 25 at 5:58 PM
News IconEli Lilly and Company (LLY) Stake Maintained by Fifth Third Bancorp (NYSE:LLY)
mundoaguaysaneamiento.net - February 25 at 5:58 PM
finance.yahoo.com logoLILLY ELI & CO Financials (NYSE:LLY)
finance.yahoo.com - February 25 at 5:58 PM
News IconGlobal Insulin Lispro Market: Eli Lilly and Company - DailyHover - DailyHover (NYSE:LLY)
dailyhover.com - February 25 at 8:22 AM
News IconThe Technical Facts on Eli Lilly and Company (LLY) - The USA Commerce (NYSE:LLY)
www.theusacommerce.com - February 25 at 8:22 AM
marketrealist.com logoEli Lilly & Co.'s Revenues in 4Q16 - Market Realist (NYSE:LLY)
marketrealist.com - February 25 at 8:22 AM
News IconCanadian Pharmacy online - Viagra Without A Doctor Prescription - Viagra And Alcohol - 3,189 Completed ORDERS Today! (NYSE:LLY)
conversationalreading.com - February 25 at 12:35 AM
News IconIndiana Patent Litigation: Trial Court Grants Stay in Axiron Lawsuit (NYSE:LLY)
www.iniplaw.org - February 25 at 12:35 AM
News IconTadalafil 20 Mg - Liquid Viagra - Canadian Pharmacies - 3,939 Completed ORDERS Today! (NYSE:LLY)
arseblog.com - February 25 at 12:35 AM
News IconEulexin Pi - Etodolac Discontinued - Eulexin For Pcos - 5,765 Completed ORDERS Today! (NYSE:LLY)
hpherald.com - February 24 at 7:33 PM
News IconAndrews Pharmacy - Ucsd Pharmacy - Mtm Pharmacy - 5,203 Completed ORDERS Today! (NYSE:LLY)
www.interfanzone.com - February 24 at 7:33 PM
News IconMicronase Company - Micronase Sales - Micronase Side Effects - 7,347 Completed ORDERS Today! (NYSE:LLY)
news.arseblog.com - February 24 at 7:33 PM
News IconGeneric Viagra onlie coupon - viagra for sale - viagra sale - 5,868 Completed ORDERS Today! (NYSE:LLY)
hpherald.com - February 24 at 9:42 AM
News IconAlavert Interactions - Alavert Tablets - Alavert Pregnancy - 2,943 Completed ORDERS Today! (NYSE:LLY)
mytwomums.com - February 24 at 9:42 AM
News IconGeneric Levitra - Cialis Coupons - Online Viagra - 7,557 Completed ORDERS Today! (NYSE:LLY)
destinationluxury.com - February 24 at 9:42 AM
News IconViagra Generic Without A Doctor Prescription - best place to buy cialis - best way to take cialis - 4,576 Completed ORDERS Today! (NYSE:LLY)
www.newscyclesolutions.com - February 24 at 9:42 AM
marketrealist.com logoPerformance of Eli Lilly & Co.’s Business Segments in 4Q16 (NYSE:LLY)
marketrealist.com - February 24 at 9:42 AM
marketrealist.com logoEli Lilly & Co.’s Endocrine Franchise (NYSE:LLY)
marketrealist.com - February 24 at 9:42 AM
News IconBuy generic Viagra onlie price - online pharmacy viagra - viagra online pharmacy - 7,657 Completed ORDERS Today! (NYSE:LLY)
mytwomums.com - February 23 at 11:24 PM
News IconCialis Online - Cialis Dosage - Cialis 20Mg - 4,866 Completed ORDERS Today! (NYSE:LLY)
hpherald.com - February 23 at 11:24 PM
News IconCialis 20Mg - Canadian Viagra - Viagra Online - 1,796 Completed ORDERS Today! (NYSE:LLY)
www.joesdaily.com - February 23 at 6:19 PM
News IconGeneric Cialis onlie coupon - purchase cialis online canada - cialis no prescription - 8,617 Completed ORDERS Today! (NYSE:LLY)
www.littlesunnykitchen.com - February 23 at 6:19 PM
News IconActos Case - Adalat Cc - Adalat Medication - 1,595 Completed ORDERS Today! (NYSE:LLY)
www.hollywoodnewsdaily.com - February 23 at 6:19 PM
marketrealist.com logoEli Lilly & Co.’s Revenues in 4Q16 (NYSE:LLY)
marketrealist.com - February 23 at 6:19 PM
News IconSlimex Online - Slimex 15Mg - Slimex 15 - 5,521 Completed ORDERS Today! (NYSE:LLY)
www.prettyprudent.com - February 23 at 5:46 AM
News IconRoxithromycin And Alcohol - Roxithromycin Tablets - Rumalaya Gel - 8,863 Completed ORDERS Today! (NYSE:LLY)
www.netnewsledger.com - February 23 at 5:46 AM
News IconActos Points - Actos Case - Adalat Cc - 1,852 Completed ORDERS Today! (NYSE:LLY)
haitiantimes.com - February 23 at 5:46 AM
News IconGeneric Viagra Online - Female Viagra - Otc Viagra - 7,597 Completed ORDERS Today! (NYSE:LLY)
www.interfanzone.com - February 23 at 5:46 AM
News IconDrug Manufacturers – Major: Eli Lilly and Company (NYSE:LLY) Position of the day (NYSE:LLY)
twincountynews.com - February 23 at 5:46 AM
News IconNavarro Discount Pharmacy Miami Fl - Lewis Pharmacy - Thompsons Pharmacy - 1,605 Completed ORDERS Today! (NYSE:LLY)
www.paintedteacup.com - February 22 at 11:28 PM
News IconHyaluronic Acid Benefits - Hyaluronic Acid Supplements - Hyaluronic Acid And Vitamin C - 6,917 Completed ORDERS Today! (NYSE:LLY)
news.arseblog.com - February 22 at 11:28 PM
News IconViagra Side Effects - buy viagra online usa - buy viagra now - 7,297 Completed ORDERS Today! (NYSE:LLY)
www.littlesunnykitchen.com - February 22 at 11:28 PM
News IconGeneric Viagra Without A Doctor Prescription Safe - Viagra Vs Cialis - Levitra Dosage - 1,202 Completed ORDERS Today! (NYSE:LLY)
www.netnewsledger.com - February 22 at 11:28 PM
openpr.com logoGrowth Hormone Drug Market 2017 - Eli Lilly and Company, Ferring Holding SA, Genentech, Inc., GeneScience Pharmaceuticals Co., Merck Serono SA (NYSE:LLY)
www.openpr.com - February 22 at 11:28 PM
News IconReminyl Medication - Reminyl Pronunciation - Renagel Cost - 6,267 Completed ORDERS Today! (NYSE:LLY)
www.prettyprudent.com - February 22 at 11:28 PM
seekingalpha.com logoEli Lilly and Company (LLY) (NYSE:LLY)
seekingalpha.com - February 22 at 6:27 PM
News IconViagra Side Effects - viagra reviews - viagra and alcohol - 8,160 Completed ORDERS Today! (NYSE:LLY)
www.netnewsledger.com - February 22 at 6:27 PM
News IconSildenafil Generic - Levitra Dosage - Viagra Generic Without A Doctor Prescription - 3,534 Completed ORDERS Today! (NYSE:LLY)
www.paintedteacup.com - February 22 at 6:27 PM
News IconFlagyl Side Effects - Flagyl Dosage - Flagyl And Alcohol - 8,679 Completed ORDERS Today! (NYSE:LLY)
news.arseblog.com - February 22 at 6:27 PM
News IconStock Price of Eli Lilly and Company (LLY) Increases 3.34% (NYSE:LLY)
naijaoversabi.com - February 22 at 6:27 PM
News IconBaricitinib Might Offer Oral Alternative to Adalimumab in RA (NYSE:LLY)
www.medscape.com - February 22 at 6:27 PM
News IconEli Lilly and Company (LLY) Position Raised by Cadence Capital Management LLC (NYSE:LLY)
www.graffiotech.com - February 22 at 6:27 PM
News IconEli Lilly and Company (NYSE:LLY)
ekosvoice.com - February 22 at 6:27 PM
cnbc.com logoEli Lilly CEO supports Trump's 'blueprint' for growth (NYSE:LLY)
www.cnbc.com - February 22 at 6:27 PM
News IconThe Must-Know Technicals As They Stand For Eli Lilly and Company (LLY) - NY Stock News (NYSE:LLY)
nystocknews.com - February 22 at 8:04 AM

Social

What is Eli Lilly and Company's stock symbol?

Eli Lilly and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?

Eli Lilly and Company announced a quarterly dividend on Tuesday, December 13th. Shareholders of record on Wednesday, February 15th will be paid a dividend of $0.52 per share on Friday, March 10th. This represents a $2.08 dividend on an annualized basis and a yield of 2.51%. The ex-dividend date of this dividend is Monday, February 13th. This is an increase from Eli Lilly and Company's previous quarterly dividend of $0.51.

Where is Eli Lilly and Company's stock going? Where will Eli Lilly and Company's stock price be in 2017?

15 brokers have issued twelve-month price objectives for Eli Lilly and Company's shares. Their forecasts range from $73.00 to $100.00. On average, they anticipate Eli Lilly and Company's share price to reach $87.45 in the next twelve months.

When will Eli Lilly and Company announce their earnings?

Eli Lilly and Company is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.

What are analysts saying about Eli Lilly and Company stock?

Here are some recent quotes from research analysts about Eli Lilly and Company stock:

  • According to Zacks Investment Research, "Lilly’s fourth-quarter results were mixed with earnings missing estimates but revenues beating the same.   Earnings jumped 22% year over year backed by strong diabetes sales. In 2017, while new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo are expected to see higher revenues, Lilly expects some established products like Trajenta, Forteo and Humalog to continue doing well. Lilly expects to launch 20 new products between 2014 and 2023, including the launch of at least two new indications/line extensions on an average every year. Although the stock’s decline was sharper than the large cap pharma industry in 2016, it has done well in 2017. However, Alimta will continue to be impacted by competition. Other headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs in the emerging markets." (2/15/2017)

  • J P Morgan Chase & Co analysts commented, "While the FDA recommends both cognitive and function endpoints for Alzheimer's drug approvals, we would not be surprised to see a positive cognitive endpoint and a trend towards functional benefit ultimately being sufficient for approval," analyst Chris Schott wrote in a note.Outcomes And ProbabilitiesThe analyst sees more than 15 percent upside in the stock if EXP-3 study meets both primary and secondary endpoints, which he states are between a 10–20 percent probability.The analyst expects a more muted 10 percent upside if the study hits on its primary but only shows a trend on secondary endpoints (50–60 percent probability).Further, Schott predicts a 10 percent drop in stock if the study fails both endpoints (about 30 percent probability).Moreover, irrespective of the outcome of solanezumab, Schott sees a diverse range of new product opportunities supporting Eli Lilly's greater than 5 percent top-line growth target. Related Link: Apple, Eli Lilly, U.S. Steel: Fast Money Picks For September 7The analyst forecast about 6 percent top-line growth through 2020, with about 5 percent excluding risk adjusted solanezumab sales.The analyst's sales growth target is also supported by a number of $1+ billion product opportunities such as Trulicity, Jardiance, Taltz, baricitinib and abemaciclib."In aggregate, we forecast recent/upcoming new product launches to generate $11.4 billion in sales by 2020," (9/8/2016)

Who owns Eli Lilly and Company stock?

Eli Lilly and Company's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (3.89%), Franklin Resources Inc. (3.24%), Janus Capital Management LLC (0.79%), Putnam Investments LLC (0.38%), Asset Management One Co. Ltd. (0.16%) and New York State Teachers Retirement System (0.16%). Company insiders that own Eli Lilly and Company stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, R David Hoover, Stephen F Fry and Susan Mahony.

Who sold Eli Lilly and Company stock? Who is selling Eli Lilly and Company stock?

Eli Lilly and Company's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Fred Alger Management Inc., Putnam Investments LLC, Capital Guardian Trust Co., Janus Capital Management LLC, I.G. Investment Management LTD., Cadinha & Co. LLC and Gabelli Funds LLC. Company insiders that have sold Eli Lilly and Company stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes and Susan Mahony.

Who bought Eli Lilly and Company stock? Who is buying Eli Lilly and Company stock?

Eli Lilly and Company's stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., State Street Corp, Asset Management One Co. Ltd., Alyeska Investment Group L.P., Russell Investments Group Ltd., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Renaissance Technologies LLC and Senzar Asset Management LLC. Company insiders that have bought Eli Lilly and Company stock in the last two years include Jackson P Tai and R David Hoover.

How do I buy Eli Lilly and Company stock?

Shares of Eli Lilly and Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Eli Lilly and Company stock cost?

One share of Eli Lilly and Company stock can currently be purchased for approximately $82.87.

Eli Lilly and Company (NYSE:LLY) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Earnings History Chart

Earnings by Quarter for Eli Lilly and Company (NYSE:LLY)

Dividend History Chart

Dividend Payments by Quarter for Eli Lilly and Company (NYSE:LLY)

Last Updated on 2/26/2017 by MarketBeat.com Staff